

Amendments to the Specification:

Please replace the paragraph beginning at page 107, line 26, and ending at page 108, line 8, with the following redlined paragraph:

The hydrophobic drug may be combined directly with Compound₁ and/or Compound₂. Alternatively, the hydrophobic drug may be combined with a secondary carrier, *e.g.*, a micelle, where the secondary carrier assists in solubilization and/or delivery of the drug. The drug/secondary carrier mixture is then combined directly with Compound₁ and/or Compound₂, and/or added separately to the mixture of Compound₁ and Compound₂. The secondary carrier is particularly useful in those instances where the drug is hydrophobic and does not readily dissolve in water. In one embodiment (*e.g.*, in which the drug is ~~hydrophobic~~ hydrophobic), the drug is associated with a secondary carrier. Optionally, this drug/carrier combination is present in an aqueous buffer solution that is combined with Compound₁ and/or Compound₂ and/or the reaction product thereof. Suitable secondary carriers are described herein. However, a preferred secondary carrier is described in PCT International Publication No. WO 02/072150 and U.S. Patent Application No. 10/251,659.

Please replace the section header on page 141, line 8, with the following redlined section header:

EXAMPLE 23-A

Please replace the section header on page 141, line 21, with the following redlined section header:

EXAMPLE 23-B

Please replace the paragraph beginning at page 145, line 26, with the following redlined paragraph:

Fibroblasts at 70-90% confluency are trypsinized, replated at 600 cells/well in media in 96-well plates and allowed to attachment overnight. Mitoxantrone is prepared in

DMSO at a concentration of 10⁻² M and diluted 10-fold to give a range of stock concentrations ~~(10⁻⁸ M to 10⁻² M)~~ (10⁻⁸ M to 10⁻² M). Drug dilutions are diluted 1/1000 in media and added to cells to give a total volume of 200 μ L/well. Each drug concentration is tested in triplicate wells. Plates containing fibroblasts and mitoxantrone are incubated at 37°C for 72 hours (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal. Biochem. (1993) 213: 426).